Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis

International Journal of Cancer

Volumn 93, Issue 4, 2001, Pages 497-506

  Rozic, Jerry G ^a   Chakraborty, Chandan ^a   Lala, Peeyush K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Angiogenesis; Breast cancer; Cyclooxygenase; Indomethacin; Invasion; Migration; NSAIDs; Prostaglandins

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GROWTH FACTOR; INDOMETACIN; MATRIGEL; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VALERYL SALICYLATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; LONG TERM CARE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; TUMOR GROWTH;

ANIMALS; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; INDOMETHACIN; ISOENZYMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; SULFONAMIDES;

EID: 0035882534     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1376     Document Type: Article

References (56)

1. Prostaglandins and breast cancer
2. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells
3. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers
4. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2
5. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HeJ mice
6. Cyclooxygenase-2 gene expression in human breast cancer
7. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
8. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
9. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
10. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
11. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
12. Nonsteroidal anti-inflammatory drugs and breast cancer
13. Nested case-control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage
14. Aspirin use and reduced risk of fatal colon cancer
15. Aspirin and the risk of colorectal cancer in women
16. Indomethacin therapy abrogates prostaglandin mediated suppression of natural killer cell activity in tumor-bearing mice and prevents tumor metastasis
17. Prostaglandins and the host immune system: Application of prostaglandin inhibitors for cancer immunotherapy
18. Eradication of spontaneous and experimental adenocarcinoma metastasis with chronic indomethacin and intermittent IL-2 therapy
19. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
20. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
21. Nitric oxide promotes murine mammary tumor growth and metastasis by stimulating tumor cell migration, invasiveness and angiogenesis
22. Nitric oxide synthase inhibition by N-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors
23. Relationship of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas
24. Prostaglandin levels in human colorectal mucosa: Effects of Sulindac in patients with familial adenomatous polyposis
25. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
26. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
27. 2-mediated inactivation of various killer lineage cells by tumor bearing host macrophages
28. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and Lymphokine-activated killer cell function in patients with breast cancer
29. 2-responsive metastatic Lewis Lung Carcinoma cells
30. Effects of fatty acids on invasion through reconstituted basement membrane ("Matrigel") by a human breast cancer cell line
31. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
32. Prostaglandin endoperoxide synthases-1 and -2
33. Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2
34. Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor
35. Effects of indomethacin with or without linoleic acid on human breast cancer cells in vitro
36. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation
37. Prostaglandin E2 receptor heterogeneity and dysfunction in mammary tumor cells
38. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis
39. Alteration of prostaglandin E receptors in advanced breast tumour cell lines
40. International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
41. Stimulation of type IV collagenase expression by linoleic acid in a metastatic human breast cancer cell line
42. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases
43. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2
44. Prostaglandin production in mouse mammary tumor cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts
45. PGE2 and angiogenesis
46. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
47. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat
48. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells
49. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy
50. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide
51. Role of nitric oxide in carcinogenesis and tumor progression
52. Role of nitric oxide in tumor progression: Lessons from human tumors
53. Role of nitric oxide in tumor progression: Lessons from experimental tumors
54. Cyclooxygenase: An important transduction system for the multi-faceted roles of nitric oxide
55. Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU
56. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor